andrew huberman retatrutide on Retatrutide: What He Said and What the Data Shows Andrew D. Huberman | Stanford
Description
The US Food and Drug Administration allowed some pharmacies to compound or custom-mix versions of two GLP-1 medications, semaglutide and tirzepatide, after those drugs went into shortage in 2022
Why GLP-1 matters for metabolic health cannot be overstated
The microbiota in adaptive immune homeostasis and disease
Weight regain is the rule rather than the exception, and in many cases, the regained weight is all fat rather than a mix of fat and lean mass
The ileal brakeinhibition of jejunal motility after ileal fat perfusion in man
Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM
